PNC Financial Services Group’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
AIM
FCM
VPM
AVM
VCM
NAMA
PNC Financial Services Group's BEAM Position: Q1 2026 in Review
PNC Financial Services Group increased its Beam Therapeutics (BEAM) stake by 14% in Q1 2026, buying an estimated $4.25K and bringing the position to 1,262 shares worth $30.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3498.
PNC Financial Services Group first reported a position in BEAM in Q3 2020 and has held it in 23 quarters since. The position peaked at $748K in Q2 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.
- PNC Financial Services Group held 1,262 shares of Beam Therapeutics worth $30.1K as of Q1 2026.
- PNC Financial Services Group bought 153 Beam Therapeutics shares in Q1 2026, an estimated $4.25K.
- Beam Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #3498 holding.
- PNC Financial Services Group first reported a position in Beam Therapeutics in Q3 2020 and has held it in 23 quarters since.
- PNC Financial Services Group's Beam Therapeutics position peaked at $748K in Q2 2021.
- 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.
Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.